Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]

Michael Z Liao,1 Johannes Kast,1 Marloes Berkhout,2 Hans Prenen,3 Sandeep Dutta,4 Vijay V Upreti1 1Clinical Pharmacology, Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA; 2Amgen B.V., Breda, the Netherlands; 3Antwerp University Hospital, Edegem, Belgium; 4Clinical Pharmacolog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liao MZ, Kast J, Berkhout M, Prenen H, Dutta S, Upreti VV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	panitumumab pharmacokinetics dose-exposure relationship body weight area under the curve colorectal neoplasms Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/25ece9ce343c4273bcedfe4dba212823
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:25ece9ce343c4273bcedfe4dba212823
record_format	dspace
spelling	oai:doaj.org-article:25ece9ce343c4273bcedfe4dba2128232021-12-02T16:10:55ZIs Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]1179-1438https://doaj.org/article/25ece9ce343c4273bcedfe4dba2128232020-12-01T00:00:00Zhttps://www.dovepress.com/response-is-bodyweight-based-dosing-truly-better-than-flat-dosing-for--peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Michael Z Liao,1 Johannes Kast,1 Marloes Berkhout,2 Hans Prenen,3 Sandeep Dutta,4 Vijay V Upreti1 1Clinical Pharmacology, Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA; 2Amgen B.V., Breda, the Netherlands; 3Antwerp University Hospital, Edegem, Belgium; 4Clinical Pharmacology, Modeling & Simulation, Amgen Inc., Thousand Oaks, CA, USACorrespondence: Vijay V UpretiClinical Pharmacology, Modeling & Simulation, Amgen, 1120 Veterans Boulevard, South San Francisco, CA 94080, USAEmail vupreti@amgen.com Thank you for the opportunity to respond to the letter by Dr. Hendrikx and colleagues. We wish to thank Dr. Hendrikx and colleagues for their interest in our recent publication by Liao et al1 and their comments about the optimal dosing regimen for panitumumab. The body weight-based dosing, 6 mg/kg once every two-week (Q2W) regimen, for panitumumab as an optimal dosing regimen is fully supported by clinical study data and pharmacokinetic modeling and simulations.2   View the original paper by Liao and colleagues   This is in response to the Letter to the EditorLiao MZKast JBerkhout MPrenen HDutta SUpreti VVDove Medical Pressarticlepanitumumabpharmacokineticsdose-exposure relationshipbody weightarea under the curvecolorectal neoplasmsTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 189-190 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	panitumumab pharmacokinetics dose-exposure relationship body weight area under the curve colorectal neoplasms Therapeutics. Pharmacology RM1-950
spellingShingle	panitumumab pharmacokinetics dose-exposure relationship body weight area under the curve colorectal neoplasms Therapeutics. Pharmacology RM1-950 Liao MZ Kast J Berkhout M Prenen H Dutta S Upreti VV Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
description	Michael Z Liao,1 Johannes Kast,1 Marloes Berkhout,2 Hans Prenen,3 Sandeep Dutta,4 Vijay V Upreti1 1Clinical Pharmacology, Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA; 2Amgen B.V., Breda, the Netherlands; 3Antwerp University Hospital, Edegem, Belgium; 4Clinical Pharmacology, Modeling & Simulation, Amgen Inc., Thousand Oaks, CA, USACorrespondence: Vijay V UpretiClinical Pharmacology, Modeling & Simulation, Amgen, 1120 Veterans Boulevard, South San Francisco, CA 94080, USAEmail vupreti@amgen.com Thank you for the opportunity to respond to the letter by Dr. Hendrikx and colleagues. We wish to thank Dr. Hendrikx and colleagues for their interest in our recent publication by Liao et al1 and their comments about the optimal dosing regimen for panitumumab. The body weight-based dosing, 6 mg/kg once every two-week (Q2W) regimen, for panitumumab as an optimal dosing regimen is fully supported by clinical study data and pharmacokinetic modeling and simulations.2   View the original paper by Liao and colleagues   This is in response to the Letter to the Editor
format	article
author	Liao MZ Kast J Berkhout M Prenen H Dutta S Upreti VV
author_facet	Liao MZ Kast J Berkhout M Prenen H Dutta S Upreti VV
author_sort	Liao MZ
title	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
title_short	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
title_full	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
title_fullStr	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
title_full_unstemmed	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
title_sort	is bodyweight-based dosing truly better than flat dosing for panitumumab? [response to letter]
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/25ece9ce343c4273bcedfe4dba212823
work_keys_str_mv	AT liaomz isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabresponsetoletter AT kastj isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabresponsetoletter AT berkhoutm isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabresponsetoletter AT prenenh isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabresponsetoletter AT duttas isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabresponsetoletter AT upretivv isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabresponsetoletter
_version_	1718384397914210304

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]

Ejemplares similares